Insight Molecular Diagnostics Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
IMDX$2.50+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $8,636 | $9,432 |
| Accounts receivable, net of allowance for credit losses of $16 and $5, respectively | 1,613 | 484 |
| Inventories | 410 | — |
| Deferred financing costs | 279 | — |
| Prepaid expenses and other current assets | 821 | 643 |
| Assets held for sale | — | 139 |
| Total current assets | 11,759 | 10,698 |
| NONCURRENT ASSETS | ||
| Right-of-use and financing lease assets, net | 2,757 | 1,637 |
| Machinery and equipment, net, and construction in progress | 3,567 | 3,799 |
| Intangible assets, net | 14,607 | 56,595 |
| Restricted cash | 1,700 | 1,700 |
| Other noncurrent assets | 691 | 463 |
| TOTAL ASSETS | $35,081 | $74,892 |
| LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $2,279 | $953 |
| Accrued compensation | 1,939 | 1,649 |
| Accrued royalties | 1,116 | 1,116 |
| Accrued expenses and other current liabilities | 418 | 452 |
| Right-of-use and financing lease liabilities, current | 1,295 | 665 |
| Current liabilities of discontinued operations (Note 13) | — | 45 |
| Contingent consideration liabilities, current | 228 | 2,314 |
| Total current liabilities | 7,275 | 7,194 |
| NONCURRENT LIABILITIES | ||
| Right-of-use and financing lease liabilities, noncurrent | 2,369 | 2,204 |
| Contingent consideration liabilities, noncurrent | 37,711 | 39,900 |
| TOTAL LIABILITIES | 47,355 | 49,298 |
| Commitments and contingencies (Note 6) | ||
| Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 shares issued and outstanding at December 31, 2023; aggregate liquidation preference of $5,296 as of December 31, 2023 | — | 5,126 |
| SHAREHOLDERS’ (DEFICIT) EQUITY | ||
| Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, no par value, 230,000 shares authorized; 17,453 and 8,261 shares issued and outstanding at December 31, 2024 and 2023, respectively | 338,244 | 310,295 |
| Accumulated other comprehensive income | 21 | 49 |
| Accumulated deficit | (350,539) | (289,876) |
| Total shareholders’ (deficit) equity | (12,274) | 20,468 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY | $35,081 | $74,892 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.